Issue link: https://www.e-digitaleditions.com/i/1469783
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 32 June 2022 Inhalation SPECIAL SECTION Filling and Packaging This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. DPI development and manufacturing services Experic's experienced team provides customized and scalable filling, packaging and logistics solutions at clinical- and commercial-scale for reservoir and single-dose dry powder inhalation (DPI) devices. From early development and manufacturing for any single- dose unit, to clinical trial supplies and logistics, Experic offers services that can solve dry powder inhaler manufacturing challenges, acceler- ate time to market, and mitigate risk for products with a range of properties, particle sizes, doses and throughput requirements. Experic LLC US: +1 609 537-4040 www.expericservices.com Lab-scale and manufacturing-scale filling machines RxPack partners with Italian multinational Coster to provide filling equipment. With over 60 years of expertise in manufacturing filling machines, the Coster portfolio includes lab-scale machines as well as semi-automatic and fully automatic lines for pressur- ized metered dose inhalers (pMDIs). e machines are suitable for single- and double-stage filling, and can fill solutions and suspensions, and include specific features to accommodate green gases such as HFA152a and HFO 1234ze(E). RxPack is a leading manufacturer of pharmaceutical dispensing solutions and a global player in pMDIs and nasal drug delivery systems. RxPack Italy: sales@rxpack.it www.rxpack.eu Coster Tecnologie Speciali SpA Italy: sales.machines@coster.com www.coster.com Plasma process for treating MDI canisters H&T Presspart offers a unique plasma process— manufactured under license from Portal Medical Ltd—for treating the internal surfaces of metered dose inhaler (MDI) canisters, which can help ensure the active drug content does not stick to the canister wall. is fluorocarbon polymerization (FCP) plasma treatment process can improve the surface energy per- formance of an MDI canister, which can enhance drug stability in formulations where interactions with the aluminium substrate can lead to product degrada- tion and reduced shelf life. H&T Presspart UK: +44 1254 582233 blackburn@presspart.com www.presspart.com